Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...
Pieris Pharmaceuticals, Inc. is a, clinical-sta...
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
Our mission is to improve the lives of patients by developing novel, best-in-class...
Our mission is to improve the lives of patients...
We have specialized in dermatology, as your skin's health is our concern. We aim t...
We have specialized in dermatology, as your ski...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a specialty clinical-stage pharmaceuti...
Therapix Biosciences Ltd. (NASDAQ: TRPX) is a s...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradicat...
Exact Sciences Corp. (NASDAQ: EXAS) is committe...
Join the National Investor Network and get the latest information with your interests in mind.